BOPA 2018 | The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman
• 12 Oct 2018
At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months.
